Skip to content
A Global TIF survey on HBV and HCV infections in thalassaemia
A Global TIF Survey on HBV and HCV infections in thalassaemia
*
1.
Haemoglobinopathy/ Thalassaemia clinic/ Transfusion Centre (whichever is appropriate for your country):
(Required.)
Name of clinic:
Country:
Region:
Name of physician in charge:
Name of respondent (if different from above):
Email address of respondent:
*
2.
Is there a National Transfusion Service in your country?
(Required.)
Yes
No
3.
Which authority is responsible for quality practices in blood banks?
There is no quality control
The Ministry of Health
The National Blood transfusion service
Other (Please specify)
Other (please specify)
4.
Are there national guidelines for all blood services in your country to follow?
Yes
No
5.
Is there a national (across the country) programme for the prevention of viral hepatitis?
Yes
No
6.
What number and proportion out of the total number of your thalassaemia patients are infected with:
HBV
HCV
HBV +HCV
7.
The highest proportion of my thalassaemia patients are infected with:
HBV
HCV
HBV +HCV
8.
To date, the infected patients have received anti-viral treatment:
For HBV
For HCV
9.
To date, what proportion of the infected patients have received anti-viral treatment:
For HBV:
For HCV:
10.
What are the criteria for providing antiviral treatment to infected thalassaemia patients in your country?
1.
2.
3.
4.
More:
11.
Has your country revised/ upgraded the treatment protocols for HBV and HCV infections?
Yes
No
12.
If yes, which drugs are registered and used in your country for HBV treatment?
1.
2.
3.
4.
5.
6.
13.
If yes to question 9, which drugs are registered and used in your country for HCV treatment?
1.
2.
3.
4.
5.
6.
Current Progress,
0 of 13 answered
